Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia

Optimization of post‐remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Medeiros, Bruno C., Chan, Steven M., Daver, Naval G., Jonas, Brian A., Pollyea, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Critical Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593671/
https://www.ncbi.nlm.nih.gov/pubmed/30945331
http://dx.doi.org/10.1002/ajh.25484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593671/
https://www.ncbi.nlm.nih.gov/pubmed/30945331
http://dx.doi.org/10.1002/ajh.25484

Ejemplares similares